summary
This study was designed to monitor the compliance of haemodialysis patients with their prescribed medicines and to analyse factors associated with non‐compliance. We conducted a transversal and descriptive study of 121 haemodialysis patients. The patient compliance to prescribed medicines was evaluated according to the percentage of tablets prescribed and taken. Gender, duration of dialysis treatment, knowledge about prescribed medicines, and family status were not related to patient compliance. However the compliance of patients younger than 65 years was 90.4% vs. 84.6% in patients over 65 years (p < 0.06) and the compliance of patients with academic knowledge was 89.6% vs. 83.7% in patients without it (p < 0.06). The most frequent cause of non‐compliance was the wrong interpretation of treatment (33.9%).
11(57.9%) patients had unique G719x mutation, while 8 patient had compound mutations (5 patients had G719+20s768I, 2 patients had G719+L861Q, and 1 patient had G719+19del). 9 (47.4%) patients gained PR, 7 (36.8%) patients gained SD, and 3 (15.8%) achieved PD, the ORR was 47.4%, and the DCR was 84.2%. The median PFS was 8.8 months (95% CI: 0.932-16.67). The median PFS of first-line TKI therapy was longer than secondline TKI therapy (10.8months vs. 4.0months respectively), but it didn't get statistical significance (p¼0.226). The median OS was 15.3 months (95%CI: 12.3-18.3), with 6 patients still alive. There were no intolerant adverse effects associating with EGFR TKIs. Conclusion: These results suggest that EGFR TKI therapy is effective in patients with G719X mutations. EGFR TKI could be a treatment choice better than chemotherapy for patients harboring G719X mutation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.